Dual antithrombotic therapy for atrial fibrillation and PCI

Affiliations

¹ Division of Cardiology, AOU Policlinico-Vittorio Emanuele, Catania 95100, Italy. Electronic address: dcapodanno@unict.it.
² Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

Comment

Davide Capodanno et al. Lancet. 2019.

. 2019 Oct 12;394(10206):1300-1302.

doi: 10.1016/S0140-6736(19)31954-3. Epub 2019 Sep 3.

¹ Division of Cardiology, AOU Policlinico-Vittorio Emanuele, Catania 95100, Italy. Electronic address: dcapodanno@unict.it.
² Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

No abstract available

Comment on

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Vranckx P, et al. Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3. Lancet. 2019. PMID: 31492505 Clinical Trial.